Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT06122649
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT06117774
- Locations
- 🇨🇳
Northern Jiangsu Peoples hospital, Yangzhou, Jiangsu, China
🇨🇳Jiangxi Cancer hospital, Nanchang, Jiangxi, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 621
- Registration Number
- NCT06104124
- Locations
- 🇺🇸
West Tennessee Research Institute, Jackson, Tennessee, United States
🇵🇪Clinica San Juan Bautista, San Juan de Lurigancho, Lima, Peru
🇵🇱Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. Dr hab. Med. Eleonory Reicher, Warszawa, Mazowieckie, Poland
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 620
- Registration Number
- NCT06054555
- Locations
- 🇭🇺
Pecsi Tudomanyegyetem Klinikai Kozpont, Szeged, Hungary
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of
🇹🇷Gazi Universitesi Tip Fakultesi Hastanesi, Yenimahalle/Ankara, Ankara, Turkey
A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT06004934
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Hialeah, Florida, United States
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 184
- Registration Number
- NCT05975073
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 750
- Registration Number
- NCT05920356
- Locations
- 🇧🇷
Associação Beneficente de Canoas, Canoas, Rio Grande Do Sul, Brazil
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳Chi Mei Hospital, Liouying, Tainan, Taiwan
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT05885451
- Locations
- 🇦🇺
Research Site, Randwick, New South Wales, Australia
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2200
- Registration Number
- NCT05882877
- Locations
- 🇧🇪
Centre Hospitalier Universitaire de Liege - Sart Tilman, Liege, Belgium
🇵🇱Centrum Zdrowia Dziecka i Rodziny Im Jana Pawla II w Sosnowcu Osrodek Badan Klinicznych, Sosnowiec, Poland
🇺🇸Cahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7297
- Registration Number
- NCT05581303
- Locations
- 🇧🇷
Hospital Santa Izabel, Salvador, Bahia, Brazil
🇨🇿Institut klinicke a experimentalni mediciny, Praha 4, Czechia
🇨🇿Milan Kvapil sro, Praha 4, Czechia